Stock Track | Insilico Medicine Soars 5.14% Intraday on China IND Approval for Rentosertib IPF Therapy

Stock Track

04/29

Insilico Medicine's stock surged 5.14% during intraday trading on Wednesday, following positive regulatory news regarding its drug development pipeline.

The significant price movement comes after the company announced that it received Investigational New Drug (IND) approval from China's Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for Rentosertib inhalation solution. The therapy is intended for the treatment of idiopathic pulmonary fibrosis (IPF) in adults.

This regulatory clearance enables Insilico Medicine to proceed with a Phase I clinical study to assess the safety, tolerability, and pharmacokinetics of the inhaled formulation, with approximately 80 subjects planned. Rentosertib had previously received orphan drug designation from the U.S. FDA for IPF in February 2023 and was added to China's breakthrough therapy designation list in May 2025.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1146903525"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1146903525\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1146903525?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-29 14:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1146903525","market":"nz","top_or_hot":-1,"title":"Stock Track | Insilico Medicine Soars 5.14% Intraday on China IND Approval for Rentosertib IPF Therapy","media":"Stock Track","content":"<p>Insilico Medicine's stock surged 5.14% during intraday trading on Wednesday, following positive regulatory news regarding its drug development pipeline.</p><p>The significant price movement comes after the company announced that it received Investigational New Drug (IND) approval from China's Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for Rentosertib inhalation solution. The therapy is intended for the treatment of idiopathic pulmonary fibrosis (IPF) in adults.</p><p>This regulatory clearance enables Insilico Medicine to proceed with a Phase I clinical study to assess the safety, tolerability, and pharmacokinetics of the inhaled formulation, with approximately 80 subjects planned. Rentosertib had previously received orphan drug designation from the U.S. FDA for IPF in February 2023 and was added to China's breakthrough therapy designation list in May 2025.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Insilico Medicine Soars 5.14% Intraday on China IND Approval for Rentosertib IPF Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Insilico Medicine Soars 5.14% Intraday on China IND Approval for Rentosertib IPF Therapy\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-04-29 14:27</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Insilico Medicine's stock surged 5.14% during intraday trading on Wednesday, following positive regulatory news regarding its drug development pipeline.</p><p>The significant price movement comes after the company announced that it received Investigational New Drug (IND) approval from China's Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for Rentosertib inhalation solution. The therapy is intended for the treatment of idiopathic pulmonary fibrosis (IPF) in adults.</p><p>This regulatory clearance enables Insilico Medicine to proceed with a Phase I clinical study to assess the safety, tolerability, and pharmacokinetics of the inhaled formulation, with approximately 80 subjects planned. Rentosertib had previously received orphan drug designation from the U.S. FDA for IPF in February 2023 and was added to China's breakthrough therapy designation list in May 2025.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03696","symbol_name":"英矽智能","start_time":0,"source_url":"","article_id":"1146903525","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1146903525","pubTimestamp":1777444041,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Insilico Medicine's stock surged 5.14% during intraday trading on Wednesday, following positive regulatory news regarding its drug development pipeline.The significant price movement comes after the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03696":"英矽智能"},"translate_title":"个股追踪|英矽智能盘中大涨5.14%因Rentosertib IPF疗法获中国IND批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03696":1},"content_text":"Insilico Medicine's stock surged 5.14% during intraday trading on Wednesday, following positive regulatory news regarding its drug development pipeline.The significant price movement comes after the company announced that it received Investigational New Drug (IND) approval from China's Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for Rentosertib inhalation solution. The therapy is intended for the treatment of idiopathic pulmonary fibrosis (IPF) in adults.This regulatory clearance enables Insilico Medicine to proceed with a Phase I clinical study to assess the safety, tolerability, and pharmacokinetics of the inhaled formulation, with approximately 80 subjects planned. Rentosertib had previously received orphan drug designation from the U.S. FDA for IPF in February 2023 and was added to China's breakthrough therapy designation list in May 2025.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}